Literature DB >> 26482408

Oral Immunization with a Recombinant Lactococcus lactis-Expressing HIV-1 Antigen on Group A Streptococcus Pilus Induces Strong Mucosal Immunity in the Gut.

Venkateswarlu Chamcha1, Andrew Jones1, Bernard R Quigley2, June R Scott2, Rama Rao Amara3.   

Abstract

The induction of a potent humoral and cellular immune response in mucosal tissue is important for the development of an effective HIV vaccine. Most of the current HIV vaccines under development use the i.m. route for immunization, which is relatively poor in generating potent and long-lived mucosal immune responses. In this article, we explore the ability of an oral vaccination with a probiotic organism, Lactococcus lactis, to elicit HIV-specific immune responses in the mucosal and systemic compartments of BALB/c mice. We expressed the HIV-1 Gag-p24 on the tip of the T3 pilus of Streptococcus pyogenes as a fusion to the Cpa protein (LL-Gag). After four monthly LL-Gag oral immunizations, we observed strong Gag-specific IgG and IgA responses in serum, feces, and vaginal secretions. However, the Gag-specific CD8 T cell responses in the blood were at or below our detection limit. After an i.m. modified vaccinia Ankara/Gag boost, we observed robust Gag-specific CD8 T cell responses both in systemic and in mucosal tissues, including intraepithelial and lamina propria lymphocytes of the small intestine, Peyer's patches, and mesenteric lymph nodes. Consistent with strong immunogenicity, the LL-Gag induced activation of CD11c(+) CD11b(+) dendritic cells in the Peyer's patches after oral immunization. Our results demonstrate that oral immunization with L. lactis expressing an Ag on the tip of the group A Streptococcus pilus serves as an excellent vaccine platform to induce strong mucosal humoral and cellular immunity against HIV.
Copyright © 2015 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26482408      PMCID: PMC4637245          DOI: 10.4049/jimmunol.1501243

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  49 in total

1.  Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

Authors:  R R Amara; F Villinger; J D Altman; S L Lydy; S P O'Neil; S I Staprans; D C Montefiori; Y Xu; J G Herndon; L S Wyatt; M A Candido; N L Kozyr; P L Earl; J M Smith; H L Ma; B D Grimm; M L Hulsey; J Miller; H M McClure; J M McNicholl; B Moss; H L Robinson
Journal:  Science       Date:  2001-04-06       Impact factor: 47.728

Review 2.  Anatomical basis of tolerance and immunity to intestinal antigens.

Authors:  Allan McI Mowat
Journal:  Nat Rev Immunol       Date:  2003-04       Impact factor: 53.106

3.  Divergent immunoglobulin g subclass activity through selective Fc receptor binding.

Authors:  Falk Nimmerjahn; Jeffrey V Ravetch
Journal:  Science       Date:  2005-12-02       Impact factor: 47.728

Review 4.  Progress and obstacles in the development of an AIDS vaccine.

Authors:  Norman L Letvin
Journal:  Nat Rev Immunol       Date:  2006-12       Impact factor: 53.106

5.  Comparative evaluation of oral and intranasal priming with replication-competent adenovirus 5 host range mutant (Ad5hr)-simian immunodeficiency virus (SIV) recombinant vaccines on immunogenicity and protective efficacy against SIV(mac251).

Authors:  Qifeng Zhou; Rachmat Hidajat; Bo Peng; David Venzon; M Kristine Aldrich; Ersell Richardson; Eun Mi Lee; V S Kalyanaraman; George Grimes; V Raúl Gómez-Román; L Ebonita Summers; Nina Malkevich; Marjorie Robert-Guroff
Journal:  Vaccine       Date:  2007-09-29       Impact factor: 3.641

6.  Different pathways of differentiation of pre-B cell lines are induced by dendritic cells and T cells from different lymphoid tissues.

Authors:  D M Spalding; J A Griffin
Journal:  Cell       Date:  1986-02-14       Impact factor: 41.582

Review 7.  The role of antibodies in HIV vaccines.

Authors:  John R Mascola; David C Montefiori
Journal:  Annu Rev Immunol       Date:  2010       Impact factor: 28.527

8.  Immunogenicity and protective efficacy of orally administered recombinant Lactococcus lactis expressing surface-bound HIV Env.

Authors:  Ke-Qin Xin; Yuka Hoshino; Yoshihiko Toda; Shizunobu Igimi; Yoshitsugu Kojima; Nao Jounai; Kenji Ohba; Akira Kushiro; Mayumi Kiwaki; Kenji Hamajima; Dennis Klinman; Kenji Okuda
Journal:  Blood       Date:  2003-03-20       Impact factor: 22.113

Review 9.  Immunobiology of mucosal HIV infection and the basis for development of a new generation of mucosal AIDS vaccines.

Authors:  Igor M Belyakov; Jay A Berzofsky
Journal:  Immunity       Date:  2004-03       Impact factor: 31.745

10.  Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination.

Authors:  Nicole L Yates; Hua-Xin Liao; Youyi Fong; Allan deCamp; Nathan A Vandergrift; William T Williams; S Munir Alam; Guido Ferrari; Zhi-yong Yang; Kelly E Seaton; Phillip W Berman; Michael D Alpert; David T Evans; Robert J O'Connell; Donald Francis; Faruk Sinangil; Carter Lee; Sorachai Nitayaphan; Supachai Rerks-Ngarm; Jaranit Kaewkungwal; Punnee Pitisuttithum; James Tartaglia; Abraham Pinter; Susan Zolla-Pazner; Peter B Gilbert; Gary J Nabel; Nelson L Michael; Jerome H Kim; David C Montefiori; Barton F Haynes; Georgia D Tomaras
Journal:  Sci Transl Med       Date:  2014-03-19       Impact factor: 17.956

View more
  15 in total

Review 1.  Vaccination against Salmonella Infection: the Mucosal Way.

Authors:  Rémi Gayet; Gilles Bioley; Nicolas Rochereau; Stéphane Paul; Blaise Corthésy
Journal:  Microbiol Mol Biol Rev       Date:  2017-06-14       Impact factor: 11.056

Review 2.  Engineering living therapeutics with synthetic biology.

Authors:  Andres Cubillos-Ruiz; Tingxi Guo; Anna Sokolovska; Paul F Miller; James J Collins; Timothy K Lu; Jose M Lora
Journal:  Nat Rev Drug Discov       Date:  2021-10-06       Impact factor: 84.694

3.  Means to Facilitate the Overcoming of Gastric Juice Barrier by a Therapeutic Staphylococcal Bacteriophage A5/80.

Authors:  Ryszard Międzybrodzki; Marlena Kłak; Ewa Jończyk-Matysiak; Barbara Bubak; Anna Wójcik; Marta Kaszowska; Beata Weber-Dąbrowska; Małgorzata Łobocka; Andrzej Górski
Journal:  Front Microbiol       Date:  2017-03-23       Impact factor: 5.640

Review 4.  A review on Lactococcus lactis: from food to factory.

Authors:  Adelene Ai-Lian Song; Lionel L A In; Swee Hua Erin Lim; Raha Abdul Rahim
Journal:  Microb Cell Fact       Date:  2017-04-04       Impact factor: 5.328

Review 5.  Coinfections and comorbidities in African health systems: At the interface of infectious and noninfectious diseases.

Authors:  Derick Nii Mensah Osakunor; David Moinina Sengeh; Francisca Mutapi
Journal:  PLoS Negl Trop Dis       Date:  2018-09-20

Review 6.  Live Bacterial Vectors-A Promising DNA Vaccine Delivery System.

Authors:  Valentina Yurina
Journal:  Med Sci (Basel)       Date:  2018-03-23

7.  SARS-CoV-2 RBD trimer protein adjuvanted with Alum-3M-052 protects from SARS-CoV-2 infection and immune pathology in the lung.

Authors:  Nanda Kishore Routhu; Narayanaiah Cheedarla; Venkata Satish Bollimpelli; Sailaja Gangadhara; Venkata Viswanadh Edara; Lilin Lai; Anusmita Sahoo; Ayalnesh Shiferaw; Tiffany M Styles; Katharine Floyd; Stephanie Fischinger; Caroline Atyeo; Sally A Shin; Sanjeev Gumber; Shannon Kirejczyk; Kenneth H Dinnon; Pei-Yong Shi; Vineet D Menachery; Mark Tomai; Christopher B Fox; Galit Alter; Thomas H Vanderford; Lisa Gralinski; Mehul S Suthar; Rama Rao Amara
Journal:  Nat Commun       Date:  2021-06-11       Impact factor: 14.919

8.  Protective Immunity Against Enterotoxigenic Escherichia coli by Oral Vaccination of Engineered Lactococcus lactis.

Authors:  Homa Ahmadi Rouzbahani; Seyed Latif Mousavi Gargari; Shahram Nazarian; Sajad Abdollahi
Journal:  Curr Microbiol       Date:  2021-07-15       Impact factor: 2.188

9.  PilVax - a novel peptide delivery platform for the development of mucosal vaccines.

Authors:  Dasun Wagachchi; Jia-Yun C Tsai; Callum Chalmers; Sam Blanchett; Jacelyn M S Loh; Thomas Proft
Journal:  Sci Rep       Date:  2018-02-07       Impact factor: 4.379

10.  Lactococcus lactis expressing sand fly PpSP15 salivary protein confers long-term protection against Leishmania major in BALB/c mice.

Authors:  Elaheh Davarpanah; Negar Seyed; Fariborz Bahrami; Sima Rafati; Reza Safaralizadeh; Tahereh Taheri
Journal:  PLoS Negl Trop Dis       Date:  2020-01-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.